Short description
Harpoon Therapeutics is a clinical-stage immunotherapy company focused on the development of novel T-cell recruiting biologic therapies.
Description
Harpoon Therapeutics is a clinical-stage immunotherapy company developing a novel class of T cell engagers that harness the power of the body’s immune system to treat patients suffering from cancer and other diseases. T cell engagers are engineered proteins that direct a patient’s own T cells to kill target cells that express specific proteins, or antigens, carried by the target cells. Using its proprietary Tri-specific T cell Activating Construct (TriTAC), platform, Harpoon is developing a pipeline of novel T cell engagers, or TriTACs, initially focused on the treatment of solid tumors and hematologic malignancies. Harpoon's first drug candidate, HPN424, is currently in Phase 1 clinical trial as a treatment for prostate cancer.
Last funding
No Way
Sign in for full access
Total funding
$$3123123
Sign in for full access
Location
South San Francisco, California, United States, North America
Founded on
January 1, 2015
Exited on
February 7, 2019
Went public on
February 7, 2019
Stock symbol
HARP
Non-profit?
No
Acquired?
No
Employees count
101-250
Revenue range
$7890 - 12340
Sign in for full access
Investors
No Way, Absolutely Noaccess, Blurry Noaccess, Noaccess, Cannot Access, Blurry Noaccess, Noaccess, Uh Ohhhh, Noaccess, Nopepepe, Noaccessforu, No Way, Noway Youcantaccess, Cannot Access, Noaccessforu, Cannot Access, No Way, No Way, No Way
Sign in for full access
Founders
Luke Evnin, Patrick Baeuerle